Find the right fit for you - faster
Get tailored insights about working at ImmPACT Bio in one quick step.
ImmPACT Bio Snapshot
We aspire to cure cancer, autoimmune diseases and other severe conditions…for everyone.
Push the limits and deliver on the promise of immune cell therapies to empower patients to live to the fullest.
Push the limits and deliver on the promise of immune cell therapies to empower patients to live to the fullest.
ImmPACT Bio USA, Inc., is a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients. The company’s logic-gate-based chimeric antigen receptor (CAR) T-cell platforms, licensed from University of California, Los Angeles (UCLA) Technology Development Group, are specifically designed to address antigen escape, reduce toxicity, overcome immunosuppression in the tumor microenvironment, and improve cell persistence. The company’s technology is based on the work of pioneering scientists, Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from UCLA. For more information, visit http://www.immpact-bio.com.
